上皮性卵巢癌女性患者治疗前全身免疫炎症指数的预后性能
Prognostic performance of pretreatment systemic immune-inflammation index in women with epithelial ovarian cancer.
作者信息
Okunade Kehinde S, John-Olabode Sarah O, Soibi-Harry Adaiah P, Okoro Austin C, Adejimi Adebola A, Ademuyiwa Iyabo Y, Osunwusi Benedetto, Adelabu Hameed, Salako Omolola
机构信息
Department of Obstetrics & Gynaecology, College of Medicine, University of Lagos, Surulere, Lagos, Nigeria.
Department of Obstetrics & Gynaecology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria.
出版信息
Future Sci OA. 2023 Aug 28;9(10):FSO897. doi: 10.2144/fsoa-2023-0108. eCollection 2023 Dec.
PURPOSE
This study investigated the prognostic performance of the systemic immune-inflammation index (SII) in patients with epithelial ovarian cancer (EOC) in Lagos, Nigeria.
METHODS
We performed a secondary analysis of the data of 91 women who had treatment for EOC between 2009 and 2018. The associations between pretreatment SII and survivals were tested.
RESULTS
Pretreatment SII more than 610.2 was a significant independent predictor of reduced progression-free survival (HR = 2.68; 95% CI, 1.17 to 6.09) while SII greater than 649.0 was a significant independent predictor of reduced 3-year overall survival (HR = 2.01; 95% CI, 1.01 to 3.99).
CONCLUSION
These findings suggest that high SII may be a potential prognostic indicator and useful marker for more intensive surveillance and design of personalized treatment in patients with EOC.
目的
本研究调查了全身免疫炎症指数（SII）在尼日利亚拉各斯上皮性卵巢癌（EOC）患者中的预后表现。
方法
我们对2009年至2018年间接受EOC治疗的91名女性的数据进行了二次分析。测试了治疗前SII与生存率之间的关联。
结果
治疗前SII大于610.2是无进展生存期缩短的显著独立预测因素（HR = 2.68；95% CI，1.17至6.09），而SII大于649.0是3年总生存期缩短的显著独立预测因素（HR = 2.01；95% CI，1.01至3.99）。
结论
这些发现表明，高SII可能是EOC患者进行更强化监测和个性化治疗设计的潜在预后指标和有用标志物。
Zotero 插件